The invention pertains to cross-neutralizing vaccines against human respiratory syncytial virus subtypes A and B employing immunogenic G protein subunit and fragments thereof that are preferably derived from the ectodomain. Various candidate G protein subunits are provided spanning amino acid sequence 67-298 of RSV G protein and combinations thereof. Also envisioned within the scope of this invention are tandem repeated recombinant G protein subunit vaccines that provide higher immunogenicity. Recombinant G protein can be codon optimized for expression in various hosts (e.g., mammalian cells or E. coli).
Potential Commercial Applications:
- Childhood vaccine
- Cross neutralizing
PCT Application No. PCT/US2014/068144
The Food and Drug Administration, Center for Biologics Evaluation and Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize RSV G protein subunit vaccine. For collaboration opportunities, please contact Surender Khurana, Ph.D. at 301-827-0739.
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
OTT Reference No: E-735-2013/0
Updated: August 4, 2015